Jia Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jia Zhu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Boxuan Zhou
Department of Breast Surgery, the First Affiliated Hospital of Gannan Medical University, Ganzhou, China
1 shared publication- Fang Zheng
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
1 shared publication Guie Lai
Department of Breast Surgery, the First Affiliated Hospital of Gannan Medical University, Ganzhou, China
1 shared publication- Jianxin He
Department of Ultrasound Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, PR China
1 shared publication - Liping Yan
Department of Breast Surgery, Jiangxi Maternal and Child Health Hospital, Nanchang, PR China; Key Laboratory of High Incidence Tumor Prevention and Treatment Guangxi Medical University, Nanning, PR China
1 shared publication - Qixing Tan
Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
1 shared publication
Latest Publications
- Open Access
- 4 December 2025
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 14 (2) , 102361
Contrast-enhanced ultrasound combined with ultra-high-frequency ultrasound improves preoperative planning for lymphovenous anastomosis: A pilot study
- 4 December 2025
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 14 (2) , 102361
Open AccessContrast-enhanced ultrasound combined with ultra-high-frequency ultrasound improves preoperative planning for lymphovenous anastomosis: A pilot study
- Open Access
- 15 July 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 241, 117128
Gut microbiota and glycochenodeoxycholic role in liver metastasis of breast cancer
- 15 July 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 241, 117128
Open AccessGut microbiota and glycochenodeoxycholic role in liver metastasis of breast cancer
- Open Access
- 17 February 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-19
Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-𝜅B-IL-6 axis of tumor-associated macrophages
Background: Circular RNAs (circRNAs) have important regulatory functions in cancer, but the role of circRNAs in the tumor microenvironment (TME) remains unclear. Moreover, we also explore the effects of si-circRNAs loaded in nanoparticles as therapeutic agent for anti-tumor in vivo. Methods: We conducted bioinformatics analysis, qRT-PCR, EdU assays, Transwell assays, co-culture system and multiple orthotopic xenograft models to investigate the expression and function of circRNAs. Additionally, PLGA-based nanoparticles loaded with si-circRNAs were used to evaluate the potential of nanotherapeutic strategy in anti-tumor response. Results: We identified oncogene SERPINE2 derived circRNA, named as cSERPINE2, which was notably elevated in breast cancer and was closely related to poor clinical outcome. Functionally, tumor exosomal cSERPINE2 was shuttled to tumor associated macrophages (TAMs) and enhanced the secretion of Interleukin-6 (IL-6), leading to increased proliferation and invasion of breast cancer cells. Furthermore, IL-6 in turn increased the EIF4A3 and CCL2 levels within tumor cells in a positive feedback mechanism, further enhancing tumor cSERPINE2 biogenesis and promoting the recruitment of TAMs. More importantly, we developed a PLGA-based nanoparticle loaded with si-cSERPINE2, which effectively attenuated breast cancer progression in vivo. Conclusions: Our study illustrates a novel mechanism that tumor exosomal cSERPINE2 mediates a positive feedback loop between tumor cells and TAMs to promote cancer progression, which may serve as a promising nanotherapeutic strategy for the treatment of breast cancer.
- 17 February 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-19
Open AccessTargeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-𝜅B-IL-6 axis of tumor-associated macrophages
Background: Circular RNAs (circRNAs) have important regulatory functions in cancer, but the role of circRNAs in the tumor microenvironment (TME) remains unclear. Moreover, we also explore the effects of si-circRNAs loaded in nanoparticles as therapeutic agent for anti-tumor in vivo. Methods: We conducted bioinformatics analysis, qRT-PCR, EdU assays, Transwell assays, co-culture system and multiple orthotopic xenograft models to investigate the expression and function of circRNAs. Additionally, PLGA-based nanoparticles loaded with si-circRNAs were used to evaluate the potential of nanotherapeutic strategy in anti-tumor response. Results: We identified oncogene SERPINE2 derived circRNA, named as cSERPINE2, which was notably elevated in breast cancer and was closely related to poor clinical outcome. Functionally, tumor exosomal cSERPINE2 was shuttled to tumor associated macrophages (TAMs) and enhanced the secretion of Interleukin-6 (IL-6), leading to increased proliferation and invasion of breast cancer cells. Furthermore, IL-6 in turn increased the EIF4A3 and CCL2 levels within tumor cells in a positive feedback mechanism, further enhancing tumor cSERPINE2 biogenesis and promoting the recruitment of TAMs. More importantly, we developed a PLGA-based nanoparticle loaded with si-cSERPINE2, which effectively attenuated breast cancer progression in vivo. Conclusions: Our study illustrates a novel mechanism that tumor exosomal cSERPINE2 mediates a positive feedback loop between tumor cells and TAMs to promote cancer progression, which may serve as a promising nanotherapeutic strategy for the treatment of breast cancer.